Genetics Generation Advancement Corp. (TPEX:4160)
49.90
-0.30 (-0.60%)
At close: Feb 11, 2026
TPEX:4160 Revenue
Genetics Generation Advancement had revenue of 145.46M TWD in the quarter ending September 30, 2025, a decrease of -14.51%. This brings the company's revenue in the last twelve months to 589.13M, down -11.32% year-over-year. In the year 2024, Genetics Generation Advancement had annual revenue of 661.86M with 11.71% growth.
Revenue (ttm)
589.13M
Revenue Growth
-11.32%
P/S Ratio
2.26
Revenue / Employee
5.66M
Employees
104
Market Cap
1.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 661.86M | 69.36M | 11.71% |
| Dec 31, 2023 | 592.50M | 44.69M | 8.16% |
| Dec 31, 2022 | 547.81M | 28.30M | 5.45% |
| Dec 31, 2021 | 519.51M | 76.38M | 17.24% |
| Dec 31, 2020 | 443.13M | 13.75M | 3.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Rossmax International | 3.82B |
| AViTA | 896.85M |
| Excelsior Biopharma | 859.77M |
| DV Biomed | 712.61M |
| Meribank Biotech | 486.52M |
| Lagis Enterprise | 470.29M |